For the first time, researchers have shown that a certain protein becomes overabundant in pancreatic neuroendocrine tumors, allowing them to thrive. (sciencedaily.com)
Finding new treatments is critical because less than 5 percent of patients with pancreatic neuroendocrine tumors respond to everolimus, the most commonly used pharmaceutical, François said. (sciencedaily.com)
In the first set of experiments, the Johns Hopkins scientists sequenced nearly all protein - encoding genes in 10 of the 68 samples of pancreatic neuroendocrine tumors and compared these sequences with normal DNA from each patient to identify tumor - specific changes or mutations. (criticalillnessinsuranceinfo.org)